Ishita Drugs & Indus
80.71
-0.19(-0.23%)
Market Cap₹24.14 Cr
PE Ratio27.24
IndustryHealthcare
Company Performance:
1D-0.23%
1M+10.55%
6M+9.07%
1Y+2.13%
5Y+144.58%
View Company Insightsright
More news about Ishita Drugs & Indus
30Jan 26
Ishita Drugs & Industries Ltd Schedules Board Meeting on February 07, 2026 for Q3FY26 Financial Results
Ishita Drugs & Industries Ltd has scheduled a board meeting for February 07, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025. The meeting complies with SEBI Regulation 29 requirements. A trading window closure is in effect from January 1, 2026, until 48 hours after results announcement, following insider trading prevention protocols.
 no imag found
31Dec 25
Ishita Drugs & Industries Promoter Jagdish Agrawal Acquires Additional 254 Shares
Jagdish Agrawal, promoter of Ishita Drugs & Industries Ltd, acquired 254 equity shares worth ₹2,540 through open market transactions on December 29, 2025. His shareholding increased marginally from 4.40% to 4.41%, with total holding rising from 131,555 to 131,809 shares. The acquisition was disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations. The company's equity share capital remains stable at ₹2.99 crores comprising 2,990,300 shares of ₹10 each.
 no imag found
10Dec 25
Ishita Pharmaceuticals Increases Stake in Ishita Drugs & Industries to 1.02%
Ishita Pharmaceuticals has increased its stake in Ishita Drugs & Industries to 1.02% through an additional acquisition of 560 shares worth Rs. 10.00 each on December 08, 2025. This follows earlier investments, bringing the total holding to 30,550 shares from the previous 29,990 shares, representing continued strategic interest between the related pharmaceutical companies.
 no imag found
11Nov 25
Ishita Drugs & Industries Reports Mixed Q2 Results, Progresses on Facility Upgrade
Ishita Drugs & Industries Limited reported Q2 FY2026 revenue of Rs. 806.81 lakhs, up from Rs. 692.92 lakhs in Q1. However, net profit declined to Rs. 14.33 lakhs from Rs. 30.23 lakhs. The company is upgrading its manufacturing facility to comply with Revised Schedule M regulations, with Rs. 50 lakhs spent on civil construction. The project faced delays due to extended monsoon. The company maintains a strong liquidity position with Rs. 472.68 lakhs in cash and bank balances.
 no imag found
Ishita Drugs & Indus
80.71
-0.19
(-0.23%)
1 Year Returns:+2.13%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)